Literature DB >> 25954941

Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder.

Raymond W Lam1, Sagar V Parikh, Erin E Michalak, Carolyn S Dewa, Sidney H Kennedy.   

Abstract

BACKGROUND: Functional recovery is increasingly recognized as a priority in the treatment of major depressive disorder (MDD), by both clinicians and patients. However, symptom improvement remains the focus of traditional clinical trials for MDD and of the regulatory approval process for new medications and other interventions. Many studies have shown that functional outcomes do not always correspond to symptom-based outcomes.
METHODS: Representatives from clinical practice, professional societies, academia, industry, and government were invited by the Canadian Network for Mood and Anxiety Treatments to develop recommendations for the conceptualization and measurement of functional outcomes in clinical trials of MDD.
RESULTS: Definitions and conceptual frameworks to guide assessment of functioning are described, as well as research methodology applicable to the broad spectrum of treatments for MDD. Examples are given for validated instruments, including patient-reported outcome measures. Strategies for knowledge translation and dissemination are suggested and consensus recommendations summarized.
CONCLUSIONS: As the societal burden and financial costs of MDD continue to escalate, so does the need for evidence-based and cost-effective interventions that demonstrate improvement in functioning. Routine assessment of functional outcomes will benefit not only individuals with MDD but also diverse stakeholders concerned about the efficacy and cost-effectiveness of interventions.

Entities:  

Mesh:

Year:  2015        PMID: 25954941

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  21 in total

1.  STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!

Authors:  Raymond W Lam; Sidney H Kennedy
Journal:  Can J Psychiatry       Date:  2015-01       Impact factor: 4.356

Review 2.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

Review 3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.

Authors:  Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

Review 4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

Authors:  Raymond W Lam; Diane McIntosh; JianLi Wang; Murray W Enns; Theo Kolivakis; Erin E Michalak; Jitender Sareen; Wei-Yi Song; Sidney H Kennedy; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

5.  Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray.

Authors:  Heather Rozjabek; Nan Li; Holger Hartmann; Dong Jing Fu; Carla Canuso; Carol Jamieson
Journal:  J Patient Rep Outcomes       Date:  2022-07-10

6.  Emotional blunting in patients with depression. Part II: relationship with functioning, well-being, and quality of life.

Authors:  Michael Cronquist Christensen; Hongye Ren; Andrea Fagiolini
Journal:  Ann Gen Psychiatry       Date:  2022-06-20       Impact factor: 3.301

7.  Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial.

Authors:  Manish K Jha; Abu Minhajuddin; Tracy L Greer; Thomas Carmody; A John Rush; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

8.  Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.

Authors:  Emma Morton; Venkat Bhat; Peter Giacobbe; Wendy Lou; Erin E Michalak; Shane McInerney; Trisha Chakrabarty; Benicio N Frey; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Susan Rotzinger; Sidney H Kennedy; Raymond W Lam
Journal:  CNS Drugs       Date:  2021-04-16       Impact factor: 5.749

9.  Which Are the Most Burdensome Functioning Areas in Depression? A Cross-National Study.

Authors:  Kaloyan Kamenov; Francisco Felix Caballero; Marta Miret; Matilde Leonardi; Päivi Sainio; Beata Tobiasz-Adamczyk; Josep Maria Haro; Somnath Chatterji; José Luis Ayuso-Mateos; Maria Cabello
Journal:  Front Psychol       Date:  2016-08-31

10.  Utility of functioning in predicting costs of care for patients with mood and anxiety disorders: a prospective cohort study.

Authors:  Conal Twomey; Alarcos Cieza; David S Baldwin
Journal:  Int Clin Psychopharmacol       Date:  2017-07       Impact factor: 1.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.